Compounding of GLP-1 Receptor Agonists: Current Federal and State Regulatory Landscape (On-Demand Webinar)

Date: 08/01/24

Closed captions are available.

Overview: This webinar discusses current issues and regulatory considerations for the compounding of GLP-1 receptor agonists including events that led to the shortage of commercially available GLP-1 receptor agonists and the impact of the shortage on compounding. The speakers also address permissible bulk drug substances that may be used to compound GLP-1 receptor agonists, examine compounding for the medical need of individual patients, and discuss future concerns.

Learning Objectives: 

• Understand the circumstances under which a pharmacy may compound commercially available drug products.
• Be able to differentiate between permissible and non-permissible bulk drug substances for 503A compounding under FDA law.
  
• Gain an in-depth knowledge of the current state of GLP-1 receptor agonist compounding and what we can expect in the future.
  

Speaker Information:

Alexander L. Snyder, Associate Attorney, Quarles & Brady LLP

Tenille Davis, Chief Advocacy Officer, Alliance for Pharmacy Compounding

Credit Information:

CLE: The maximum number of credits available for ON DEMAND is 1.5 for a 60-minute state and 1.8 for a 50-minute state. Please note that the availability of credits may vary from state to state.  This self-study course will be available for purchase for approximately one year after the recording date, but state rules on duration of eligibility for CLE-credits differ, so please check with your state before purchasing self-study offerings. 

CPE: CPE credits are not available for on-demand.

CCB: CCB credits are not available for this on-demand webinar.